ArticleJournal of the American Geriatrics Society2020
Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Article in Journal of the American Geriatrics Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01206062 (Systolic Blood Pressure Intervention Trial), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Systolic Blood Pressure Intervention Trial
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Intensive Blood Pressure Treatment Goals: Evidence for Cardiovascular Protection From Observational Studies and Clinical Trials.American journal of hypertension · 2022Pooled it
- Evaluation of Intensive vs Standard Blood Pressure Reduction and Association With Cognitive Decline and Dementia: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Trial
- Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT.Hypertension (Dallas, Tex. : 1979) · 2023Trial
- Association Between the Frailty and Cognitive Impairment Among Patients With Hypertension-A Post Hoc Analysis of the SPRINT Trial.Journal of the American Heart Association · 2023Trial
- Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial.JAMA internal medicine · 2023Trial
- Trial
- Data sharing statements: impact of journal policies across clinical research disciplines.European heart journal · 2026Article
- The optimal blood pressure target in old and very old patients with hypertension.Age and ageing · 2026Article
- Predictors of cognitive resilience in the old-old: An observational study using real-world electronic health record data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Impact of long-term systolic blood pressure on cognitive disorder risk: Across different age groups and antihypertensive medication timing.Journal of Alzheimer's disease : JAD · 2026Observational
- Combination Therapy With Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors for Cardiovascular Diseases: Focus on Bisoprolol/Ramipril.Cardiovascular therapeutics · 2026Review
- Trends in hypertensive heart disease-related mortality among population with Alzheimer's in the United States: a 22-year nationwide analysis.Annals of medicine and surgery (2012) · 2025Review
- Comparing the "Life's Essential 8" Scores of Older Adults Living With Cardiovascular Diseases: NHANES, 2013 to 2018.Journal of the American Heart Association · 2025Article
- Is Intensive Blood Pressure Control Indicated in Older Patients with Hypertension?Current cardiology reports · 2024Review
- 2023 Guideline for the management of hypertension in the elderly population in China.Journal of geriatric cardiology : JGC · 2024Article
- Awaiting the verdict: Statins and the road ahead for primary prevention in older adults.Journal of the American Geriatrics Society · 2024Article
- Association of gait speed and handgrip strength with falls in older adults: the role of cognition.Turkish journal of medical sciences · 2024Article
- Cardiovascular Disease and Alzheimer's Disease: The Heart-Brain Axis.Journal of the American Heart Association · 2023Review
- Screening for cognitive impairment in older adults with hypertension: the HYPER-COG study.Journal of human hypertension · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 12 institutions in 3 countries.
Funding
Abstract
objectivesTo evaluate the effect of intensive systolic blood pressure (SBP) control in older adults with hypertension, considering cognitive and physical function.
designSecondary analysis.
settingSystolic Blood Pressure Intervention Trial (SPRINT)
participantsAdults 80 years or older.
interventionParticipants with hypertension but without diabetes (N = 1167) were randomized to an SBP target below 120 mm Hg (intensive treatment) vs a target below 140 mm Hg (standard treatment). MEASUREMENTS: We measured the incidence of cardiovascular disease (CVD), mortality, changes in renal function, mild cognitive impairment (MCI), probable dementia, and serious adverse events. Gait speed was assessed via a 4-m walk test, and the Montreal Cognitive Assessment (MoCA) was used to quantify baseline cognitive function.
resultsIntensive treatment led to significant reductions in cardiovascular events (hazard ratio [HR] = .66; 95% confidence interval [CI] = .49-.90), mortality (HR = .67; 95% CI = .48-.93), and MCI (HR = .70; 95% CI = .51-.96). There was a significant interaction (P < .001) whereby participants with higher baseline scores on the MoCA derived strong benefit from intensive treatment for a composite of CVD and mortality (HR = .40; 95% CI = .28-.57), with no appreciable benefit in participants with lower scores on the MoCA (HR = 1.33 = 95% CI = .87-2.03). There was no evidence of heterogeneity of treatment effects with respect to gait speed. Rates of acute kidney injury and declines of at least 30% in estimated glomerular filtration rate were increased in the intensive treatment group with no between-group differences in the rate of injurious falls.
conclusionIn adults aged 80 years or older, intensive SBP control lowers the risk of major cardiovascular events, MCI, and death, with increased risk of changes to kidney function. The cardiovascular and mortality benefits of intensive SBP control may not extend to older adults with lower baseline cognitive function.
trial registrationClinicaltrials.gov identifier: NCT01206062. J Am Geriatr Soc 68:496-504, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.